Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.

9 Apr 2013

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research has chosen Prof. Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.

9 Apr 2013

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

"In a decisive victory for India's pharmaceutical industry, India's Supreme Court rejected Novartis' patent application for the cancer drug Glivec on Monday, ending a seven-year battle by the Swiss drug maker to get a patent in India on its powerful leukemia drug," Time reports (Mahr, 4/1).

3 Apr 2013

Investigators examine effectiveness of probiotics for cancer treatment

One may not think of probiotics -- like those found in yogurt that promote good digestive health -- as a weapon used in the fight against cancer. But that is the focus of investigators at The Cancer Institute of New Jersey, who are examining the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for patients with blood cancers.

21 Mar 2013

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

21 Mar 2013

Research: Decreased levels of vitamin D may influence smokers to develop tobacco-related cancer

New research appearing online today in Clinical Chemistry, the journal of AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer.

16 Mar 2013

Targeting Mer receptors sensitize AML and ALL to chemotherapies

Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.

12 Mar 2013

Stem cell transplantation could be delayed in acute myeloid leukemia

Stem cell transplantation could be delayed until a relapse occurs, without affecting overall survival, in some patients with acute myeloid leukemia, UK researchers report.

5 Mar 2013

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).

4 Mar 2013

Two antagonistic proteins help keep leukemia at bay

Two proteins that scientists once thought carried out the same functions are actually antagonists of each other, and keeping them in balance is key to preventing diseases such as cancer, according to new findings published in the February 25 issue of Developmental Cell by scientists at Fox Chase Cancer Center.

27 Feb 2013

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

26 Feb 2013

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Charles L. Sawyers, Chair of Memorial Sloan-Kettering's Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today. The award - established by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner - recognizes "excellence in research aimed at curing intractable diseases and extending human life."

21 Feb 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

RNF20 protein required for MLL-rearranged leukemia amplification

Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics.

12 Feb 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

Myeloid Leukemia News and Research

Study identifies potential drug targets that interfere with cancer metabolism

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

American Society of Hematology announces first recipients of ASH Bridge Grants

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

Investigators examine effectiveness of probiotics for cancer treatment

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Research: Decreased levels of vitamin D may influence smokers to develop tobacco-related cancer

Targeting Mer receptors sensitize AML and ALL to chemotherapies

Stem cell transplantation could be delayed in acute myeloid leukemia

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Two antagonistic proteins help keep leukemia at bay

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

RNF20 protein required for MLL-rearranged leukemia amplification

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News